Capricor Therapeutics (NASDAQ:CAPR) Shares Gap Up – Here’s Why

Capricor Therapeutics, Inc. (NASDAQ:CAPR)’s stock price gapped up prior to trading on Tuesday . The stock had previously closed at $9.91, but opened at $10.77. Capricor Therapeutics shares last traded at $10.2510, with a volume of 1,487,566 shares changing hands.

Trending Headlines about Capricor Therapeutics

Here are the key news stories impacting Capricor Therapeutics this week:

• Positive Sentiment: Analyst upgrade: Piper Sandler upgraded Capricor, reportedly reflecting a more favorable view of the company and its lead candidate, deramiocel. The upgrade helped lift investor sentiment. Capricor Therapeutics Shares Rise After Piper Sandler Upgrade
• Neutral Sentiment: FDA review extension: Reports highlighted an extension of the FDA’s review of deramiocel, Capricor’s therapy for Duchenne muscular dystrophy-related cardiac and skeletal-muscle complications. The extension keeps the regulatory process active but delays clarity on approval and prolongs uncertainty for investors. Hagens Berman FDA Review Extension Alert
• Negative Sentiment: Legal and clinical-data overhang: Multiple law firms publicized an ongoing securities class action and a September 28, 2026 lead-plaintiff deadline. The lawsuits allege Capricor misled investors about deramiocel’s FDA approval path and the integrity of clinical data, including alleged deviations from blinding procedures, the Phase 3 HOPE-3 protocol and its statistical analysis plan. The complaints link these disclosures to a sharp prior selloff, raising potential litigation costs, reputational risk and further volatility. Levi and Korsinsky Capricor Class Action Alert

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on CAPR shares. LADENBURG THALM/SH SH lowered shares of Capricor Therapeutics from a “buy” rating to a “neutral” rating in a research report on Thursday, July 30th. B. Riley Financial lowered Capricor Therapeutics from a “buy” rating to a “neutral” rating and set a $10.00 price objective on the stock. in a research note on Monday, July 27th. Cantor Fitzgerald upgraded Capricor Therapeutics from a “neutral” rating to an “overweight” rating in a research note on Friday, August 14th. JonesTrading lowered Capricor Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, July 31st. Finally, HC Wainwright reiterated a “neutral” rating on shares of Capricor Therapeutics in a report on Monday, July 27th. Three investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Capricor Therapeutics currently has an average rating of “Hold” and an average target price of $29.15.

Capricor Therapeutics Price Performance

The stock has a market capitalization of $575.00 million, a price-to-earnings ratio of -4.04 and a beta of 0.72. The firm has a 50 day simple moving average of $13.29 and a 200-day simple moving average of $24.00.

Capricor Therapeutics (NASDAQ:CAPR) last issued its earnings results on Thursday, August 13th. The biotechnology company reported ($0.70) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.11). On average, sell-side analysts forecast that Capricor Therapeutics, Inc. will post -1.72 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Capricor Therapeutics news, CFO Anthony Bergmann sold 24,100 shares of the company’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $30.38, for a total transaction of $732,158.00. Following the sale, the chief financial officer directly owned 11,223 shares of the company’s stock, valued at approximately $340,954.74. This represents a 68.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold 25,000 shares of company stock valued at $759,158 in the last quarter. 9.20% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Russell Investments Group Ltd. raised its position in Capricor Therapeutics by 122.2% in the 3rd quarter. Russell Investments Group Ltd. now owns 5,066 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 2,786 shares during the last quarter. ACT Capital Management LLC bought a new stake in shares of Capricor Therapeutics during the fourth quarter worth $43,000. KBC Group NV acquired a new stake in shares of Capricor Therapeutics in the first quarter valued at $44,000. Tower Research Capital LLC TRC increased its stake in shares of Capricor Therapeutics by 280.8% in the second quarter. Tower Research Capital LLC TRC now owns 6,748 shares of the biotechnology company’s stock valued at $67,000 after buying an additional 4,976 shares in the last quarter. Finally, Regal Investment Advisors LLC acquired a new stake in shares of Capricor Therapeutics in the third quarter valued at $92,000. 21.68% of the stock is owned by institutional investors and hedge funds.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.